A61K 31/437
The heterocyclic ring system containing a five-membered ring having nitrogen as a
Official title: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K31/437 (The heterocyclic ring system containing a five-membered ring having nitrogen as a) appears on 3,526 US grants and 6,632 published applications in this corpus.
Search patents in A61K- Granted patents
- 3,526
- Published applications
- 6,632
- Assignees
- 2,122
- Inventors
- 14,376
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 4 | 0 |
| 1997 | 11 | 0 |
| 1998 | 14 | 0 |
| 1999 | 21 | 0 |
| 2000 | 23 | 0 |
| 2001 | 24 | 12 |
| 2002 | 33 | 40 |
| 2003 | 38 | 98 |
| 2004 | 40 | 126 |
| 2005 | 28 | 64 |
| 2006 | 63 | 73 |
| 2007 | 16 | 65 |
| 2008 | 35 | 84 |
| 2009 | 35 | 111 |
| 2010 | 25 | 148 |
| 2011 | 53 | 202 |
| 2012 | 74 | 180 |
| 2013 | 116 | 301 |
| 2014 | 165 | 337 |
| 2015 | 240 | 382 |
| 2016 | 249 | 415 |
| 2017 | 294 | 383 |
| 2018 | 287 | 405 |
| 2019 | 270 | 393 |
| 2020 | 270 | 375 |
| 2021 | 231 | 359 |
| 2022 | 188 | 395 |
| 2023 | 152 | 366 |
| 2024 | 189 | 438 |
| 2025 | 202 | 476 |
| 2026 | 132 | 404 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Oral formulations and uses thereof29 Sep 2026US 12,746,229 B2Inventisbio Co., Ltd.
- Interferon gene stimulator composition comprising indolizine derivative as active ingredient29 Sep 2026US 12,746,252 B2Ajou University Industry-Academic Cooperation Foundation
- Methods for the treatment of cancers that have acquired resistance to kinase inhibitors22 Sep 2026US 12,740,979 B2Inserm (Institut National De La Sante Et De La Recherche Medicale)
- PAI-1 inhibitors and uses thereof15 Sep 2026US 12,735,402 B2The Cleveland Clinic Foundation
- Compounds for the treatment of bacterial infections and potentiation of antibiotics8 Sep 2026US 12,728,105 B2Georgia State University Research Foundation, Inc.
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Treatment of clonal hematopoietic disorders using kinase inhibitors8 Oct 2026US 2026/0306462 A1
- Sik inhibitors to treat chronic kidney disease8 Oct 2026US 2026/0306463 A1The General Hospital Corporation
- Linaprazan glurate for treating gastroesophageal reflux disease (gerd)8 Oct 2026US 2026/0306464 A1Cinclus Pharma Holding AB (Publ)
- Compounds for treating hereditary spastic paraplegia8 Oct 2026US 2026/0306465 A1Children's Medical Center Corporation
Most cited
By later US patents
- Immune response modifier compounds for treatment of TH2 mediated and related diseases285US 6,039,969 A3M Innovative Properties Company · 2000
- Formulations and methods for treatment of mucosal associated conditions with an immune response modifier272US 6,245,776 B13M Innovative Properties Company · 2001
- Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth243US 6,861,053 B1Cedars-Sinai Medical Center · 2005
- Formulations and methods for treatment of mucosal associated conditions with an immune response modifier193US 6,486,168 B13M Innovative Properties Company · 2002
- Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof170US 7,074,801 B1Eisai Co., Ltd. · 2006